

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

04 Jun 2026

### Effect of N-acetyl cysteine on oxidative stress biochemical factors and IVF/ICSI outcomes in women with endometrioma: A randomized, double-blinded, phase III Clinical Trial

#### Protocol summary

##### Study aim

To evaluate determine the effect of N-acetyl cysteine on improving oocyte quality, reduction of stress oxidative markers, and ongoing pregnancy rate in endometrioma patients who underwent IVF/ICSI cycles

##### Design

A clinical trial with a control group (placebo), parallel group, double-blind, randomized, phase 3 on 140 patients, used 10 and 4 permutation blocks for randomization.

##### Settings and conduct

A total of 140 patients with endometrioma, eligible for the study, who underwent IVF / ICSI cycles, randomized into two groups of intervention and control (placebo) by observing ethical points. This is a double-blind study in the form of patient and researcher blindness.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: age between 20 and 42 years old; Ultrasound or laparoscopic diagnosis of moderate to severe endometrioma (endometriosis stage III and IV); Serum AMH levels between 0.7 and 4.5 ng/ml; standard long GnRH and antagonist ovulation stimulation cycle; Body mass index (BMI) <30 kg/m<sup>2</sup>. Non-inclusion criteria: congenital uterine malformations; severe male infertility (TESE, PESA); past medical history of asthma.

##### Intervention groups

Participants who randomly assigned in the intervention group, during 6 weeks simultaneous to start standard long agonist protocol or E2 priming with antagonist induction, will be received 1200 (2×600) mg of effervescent tablets of NAC daily. Blood will collect before the intervention and at the time of oocyte retrieval, in addition to, follicular fluid will be obtained from the mature follicles. Also, we measure severity of dysmenorrhea by visual analogue scale (VAS) technique.

##### Main outcome variables

MII oocyte number and quality

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210619051619N1**

Registration date: **2021-10-29, 1400/08/07**

Registration timing: **registered\_while\_recruiting**

Last update: **2021-10-29, 1400/08/07**

Update count: **0**

##### Registration date

2021-10-29, 1400/08/07

##### Registrant information

##### Name

Parvaneh Afsharian

##### Name of organization / entity

Royan Institute

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2356 2674

##### Email address

p.afsharian@royan-rc.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-04-13, 1400/01/24

##### Expected recruitment end date

2023-09-23, 1402/07/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

### Scientific title

Effect of N-acetyl cysteine on oxidative stress biochemical factors and IVF/ICSI outcomes in women with endometrioma: A randomized, double-blinded, phase III Clinical Trial

### Public title

N-acetyl cysteine and endometrioma

### Purpose

Treatment

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Age between 20 and 42 years old Ultrasound or laparoscopic diagnosis of moderate to severe endometrioma (endometriosis stage III and IV) Serum AMH levels between 0.7 and 4.5 ng/ml Standard long GnRH and antagonist ovulation stimulation cycle Body mass index (BMI) <30 kg/m<sup>2</sup>

#### Exclusion criteria:

Non-inclusion criteria: Congenital uterine malformations Severe male infertility (TESE, PESA) Past medical history of asthma

### Age

From **20 years** old to **42 years** old

### Gender

Female

### Phase

3

### Groups that have been masked

- Participant
- Care provider
- Investigator

### Sample size

Target sample size: **140**

### Randomization (investigator's opinion)

Randomized

### Randomization description

The permuted blocks is method for random allocation. The size of the blocks varies, including 10 blocks and 4 blocks. The allocation ratio is equal in both groups. As soon as the included patient a unique identification code is assigned to the patient and will not change during the study.

### Blinding (investigator's opinion)

Double blinded

### Blinding description

Participants, principle investigator, and healthcare providers do not have information about two study groups.

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Royan infertility institute

##### Street address

Number 12, East Hafez Avenue, Bani Hashem Street, Soleimani Highway, Tehran, Iran

##### City

Tehran

##### Province

Tehran

##### Postal code

1665659911

#### Approval date

2019-07-16, 1398/04/25

#### Ethics committee reference number

IR.ACECR.ROYAN.REC.1398.111

## Health conditions studied

### 1

#### Description of health condition studied

Endometrioma

#### ICD-10 code

N80.1

#### ICD-10 code description

Endometriosis of ovary

## Primary outcomes

### 1

#### Description

MII oocyte number and quality

#### Timepoint

Immediately after oocyte puncture

#### Method of measurement

Observation of oocytes that were mature at the time of oocyte collection

## Secondary outcomes

### 1

#### Description

Measurement of TAC oxidative stress marker in blood plasma

#### Timepoint

Before intervention and 6 weeks after intervention

#### Method of measurement

ELISA

### 2

#### Description

Measurement of SOD oxidative stress marker in blood plasma

### **Timepoint**

Before intervention and 6 weeks after intervention

### **Method of measurement**

ELISA

### **3**

#### **Description**

Measurement of TAC oxidative stress marker in follicular fluid

#### **Timepoint**

After oocyte puncture

#### **Method of measurement**

ELISA

### **4**

#### **Description**

Measurement of SOD oxidative stress marker in follicular fluid

#### **Timepoint**

After oocyte puncture

#### **Method of measurement**

ELISA

### **5**

#### **Description**

Cleaved embryo numbers

#### **Timepoint**

2-3 days after oocyte puncture

#### **Method of measurement**

2-3 days embryo from fertilization

### **6**

#### **Description**

Blastocyst numbers

#### **Timepoint**

5 days after oocyte puncture and sperm insemination

#### **Method of measurement**

The stage the embryo reaches after 5 days in culture from the egg retrieval

### **7**

#### **Description**

Clinical pregnancy rate

#### **Timepoint**

4-6 weeks after embryo transfer

#### **Method of measurement**

The observation of gestational sac on ultrasound examination two-three weeks after positive serum  $\beta$ hCG

### **8**

#### **Description**

Fertilization rate

#### **Timepoint**

2-5 days after sperm insemination

#### **Method of measurement**

Percentage of transformation of micro injected oocytes into two pronuclei embryo

## **Intervention groups**

### **1**

#### **Description**

Intervention group: Participants who randomly assigned in the intervention group, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction, will be received 1200 (2×600) mg of effervescent tablets of NAC daily. Blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles. Also, we will measure severity of dysmenorrhea by visual analogue scale (VAS) technique.

#### **Category**

Treatment - Drugs

### **2**

#### **Description**

Control group: Participants who randomly assigned to the control group, during 6 weeks simultaneous to start the standard long agonist protocol, or antagonist induction, will be received 1200 (2×600) mg of placebo tablets of NAC daily. Blood will collect before the intervention and at the time of oocyte retrieval, in addition to, follicular fluid will be obtained from the mature follicles. Also, we measure severity of dysmenorrhea by visual analogue scale (VAS) technique.

#### **Category**

Placebo

## **Recruitment centers**

### **1**

#### **Recruitment center**

##### **Name of recruitment center**

Royan Institute

##### **Full name of responsible person**

Abdolhossein Shahverdi

##### **Street address**

Royan alley, East Hafez Avenue, Bani Hashem Street, Soleimani Highway, Tehran, Iran

##### **City**

Tehran

##### **Province**

Tehran

##### **Postal code**

1665659911

##### **Phone**

+98 21 2356 2211

##### **Fax**

+98 21 2230 6481

##### **Email**

shahverdi@royaninstitute.org

## **Sponsors / Funding sources**

## 1

### Sponsor

**Name of organization / entity**

Royan Institute

**Full name of responsible person**

Abdolhossein Shahverdi

**Street address**

Royan alley, East Hafez Avenue, Bani Hashem Street,  
Soleimani Highway, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1665659911

**Phone**

+98 21 2356 2211

**Email**

shahverdi@royaninstitute.org

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Royan Institute

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Royan Institute

**Full name of responsible person**

Parvaneh Afsharin

**Position**

Associated professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Genetics

**Street address**

Royan alley, East Hafez Avenue, Bani Hashem Street,  
Soleimani Highway, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1665659911

**Phone**

+98 21 2356 2674

**Email**

p.afsharian@royan-rc.ac.ir

### Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Royan Institute

**Full name of responsible person**

Parvaneh Afsharian

**Position**

Associated professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Genetics

**Street address**

Royan alley, East Hafez Avenue, Bani Hashem Street,  
Soleimani Highway, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1665659911

**Phone**

+98 21 2356 2674

**Email**

p.afsharian@royan-rc.ac.ir

### Person responsible for updating data

**Contact****Name of organization / entity**

Royan Institute

**Full name of responsible person**

Zahra Chekini

**Position**

Resercher

**Latest degree**

Master

**Other areas of specialty/work**

Medical Genetics

**Street address**

Royan alley, East Hafez Avenue, Bani Hashem Street,  
Soleimani Highway, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1665659911

**Phone**

+98 21 2356 2643

**Email**

zahra\_chekini@ymail.com

### Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to

make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available